wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
CNCR.25123
CNCR.25123
http://dx.doi.org/10.1002/CNCR.25123
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
P356
Q37194640-EB33EC24-ACF6-4A1D-8F86-28566A50273F
P356
CNCR.25123
http://dx.doi.org/10.1002/CNCR.25123